Quanterix (NASDAQ:QTRX – Get Free Report) released its quarterly earnings results on Monday. The company reported ($0.46) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.04), FiscalAI reports. The business had revenue of $34.97 million during the quarter, compared to analyst estimates of $33.85 million. Quanterix had a negative return on equity of 26.09% and a negative net margin of 80.25%.
Quanterix Stock Down 0.3%
Shares of NASDAQ QTRX opened at $2.89 on Monday. The company’s 50-day simple moving average is $3.00 and its 200-day simple moving average is $3.80. Quanterix has a 52-week low of $2.15 and a 52-week high of $8.77. The firm has a market cap of $136.67 million, a price-to-earnings ratio of -1.10 and a beta of 1.06.
Analysts Set New Price Targets
Several analysts have commented on the company. Weiss Ratings reissued a “sell (e+)” rating on shares of Quanterix in a report on Wednesday. TD Cowen boosted their price objective on Quanterix from $3.00 to $3.50 and gave the company a “hold” rating in a research report on Tuesday, October 13th. Wall Street Zen downgraded Quanterix from a “hold” rating to a “sell” rating in a research note on Saturday. Finally, Canaccord Genuity Group decreased their target price on Quanterix from $4.00 to $3.00 and set a “hold” rating on the stock in a research report on Monday, August 17th. Two analysts have rated the stock with a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Reduce” and an average target price of $3.25.
Check Out Our Latest Research Report on Quanterix
Quanterix Company Profile
Quanterix Corporation (NASDAQ:QTRX) is a life sciences company that develops ultra-sensitive digital immunoassay technologies for detecting and measuring biomarkers in blood and other biological samples. Its platform is designed to identify proteins and other molecules at very low concentrations, supporting research into disease biology, diagnosis, treatment response and drug development.
The company’s principal technology, Simoa, uses digital detection methods to improve the sensitivity of immunoassays.
Read More
- Five stocks we like better than Quanterix
- America’s Rare Earth Clock Is Running Out, But the Bottleneck Isn’t Where You Think
- Atlassian Tanks After Huge Run as Guidance Disappoints, But Strength Remains
- Lemonade’s Revenue Soars 73%—So Why Did Its Stock Turn Sour After Earnings?
- Anthropic’s S-1 Strengthens the Case for Broadcom’s AI Growth
Receive News & Ratings for Quanterix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quanterix and related companies with MarketBeat.com's FREE daily email newsletter.
